A Clinical Study of Topical 2% Dorzolamide(Trusopt) as Adjunctive Therapy.

Lee, Jong Joon; Chung, Jin; Baek, Nam Ho

Original Article

Journal of the Korean Ophthalmological Society 1997;38(3):443-449.
Published online March 1, 1997.

A Clinical Study of Topical 2% Dorzolamide(Trusopt) as Adjunctive Therapy.

¹Department of Ophthalmology, Capital Armed Forces General Hospital, Seoul, Korea.
²Department of Ophthalmology, St. Mary's Hospital Catholic University Medicine College, Seoul, Korea.

보조적 요법으로 국소점안제인 2% dorzolamide(Trusopt) 사용후 임상적 고찰

이종준(Jong Joon Lee),정진(Jin Chung),백남호(Nam Ho Baek)

Abstract

We investigated the intraocular pressure(IOP) lowering effect and side effects of 2% dorzolamide(Trusopt) as adjunctive therapy in 18 eyes of 11 glaucoma patients and 10 eyes of 10 normal subjects. For those patients who have taken beta-blocker at least 2 weeks in glaucoma or ocular hypertension, we measured IOP before dorzolamide start and after dorzolamide instillation, every 2 hours from 10 AM to 4 PM for 3 weeks and evaluated the side effects. In normal subjects, we Measured the same method of IOP for 2 weeks and evaluated the side effects. In patients with glaucoma or ocular hypertension, mean IOP was lowered 4.4 mmHg after 2% dorzolamide instillation(P<0.01). There was no change in pulse rate, blood pressure and corneal sensitivity before and after instillation. There was no significant IOP lowering effect on normal subjects(p>0.05). The common side effects were bitter taste, burning sensation, redness, tearing and dryness. Above these results, we think 2% dorzolamide is effective as adjunctive therapy in glaucoma and more follow-up and treatment is needed to establish the fact.

Key Words: Dorzolamide;Glaucoma;IOP;Ocular hypertension;Side effects